Indacaterol inhibits collective cell migration and IGDQ-mediated single cell migration in metastatic breast cancer MDA-MB-231 cells

Ayama-Canden, Sophie, Tondo, Rodolfo, Pineros Leyton, Martha Liliana, Ninane, Noëlle, Demazy, Catherine, Dieu, Marc, Fattaccioli, Antoine, Sauvage, Aude, Tabarrant, Tijani, Lucas, Stéphane, Bonifazi, Davide ORCID: https://orcid.org/0000-0001-5717-0121 and Michiels, Carine 2023. Indacaterol inhibits collective cell migration and IGDQ-mediated single cell migration in metastatic breast cancer MDA-MB-231 cells. Cell Communication and Signaling 21 , 301. 10.1186/s12964-023-01340-9

	PDF - Published Version Available under License Creative Commons Attribution. Download (8MB)
	PDF - Supplemental Material Available under License Creative Commons Attribution. Download (561kB)

Abstract

Summary: Metastasis is the main cause of deaths related to breast cancer. This is particular the case for triple negative breast cancer. No targeted therapies are reported as efficient until now. The extracellular matrix, in particular the fibronectin type I motif IGDQ, plays a major role in regulating cell migration prior metastasis formation. This motif interacts with specific integrins inducing their activation and the migratory signal transduction.Here, we characterized the migratory phenotype of MDA-MB-231 cells, using functionalized IGDQ-exposing surfaces, and compared it to integrin A5 and integrin B3 knock-down cells. A multiomic analysis was developed that highlighted the splicing factor SRSF6 as a putative master regulator of cell migration and of integrin intracellular trafficking. Indacaterol-induced inhibition of SRSF6 provoked: i) the inhibition of collective and IGDQ-mediated cell migration and ii) ITGA5 sequestration into endosomes and lysosomes. Upon further studies, indacaterol may be a potential therapy to prevent cell migration and reduce metastasis formation in breast cancer. 1CRnmBvVXp9LXQy1nJKbUFVideo Abstract

Item Type:	Article
Date Type:	Published Online
Status:	Published
Schools:	Chemistry
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by/4.0/, Type: open-access
Publisher:	BioMed Central
Date of First Compliant Deposit:	31 October 2023
Date of Acceptance:	27 September 2023
Last Modified:	06 Jan 2024 04:45
URI:	https://orca.cardiff.ac.uk/id/eprint/163588

Actions (repository staff only)

Edit Item